James A. McNulty - 05 May 2023 Form 4 Insider Report for Inhibitor Therapeutics, Inc. (INTI)

Role
Chief Financial Officer, Treasurer, Secretary of the Company, 10%+ Owner
Signature
/s/ James A. McNulty
Issuer symbol
INTI
Transactions as of
05 May 2023
Net transactions value
$0
Form type
4
Filing time
17 May 2023, 19:46:15 UTC
Previous filing
22 Dec 2022
Next filing
16 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INTI Common Stock Other $0 -79,627,069 -100% $0.000000* 0 05 May 2023 See footnote F1, F2
transaction INTI Common Stock Other $0 +398,135 +73% $0.000000 946,135 05 May 2023 Direct F1, F2
transaction INTI Common Stock Other $0 +20,101,057 +335% $0.000000 26,101,057 05 May 2023 See footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares of common stock of Inhibitor Therapeutics, Inc. were distributed to the members of Hedgepath, LLC ("HPLLC"), pro-rata pursuant to their membership interest in HPLLC.
F2 Mr. McNulty was the manager of HPLLC, which distributed 79,627,069 shares of common stock to its members, pro-rata pursuant to their membership interest in HPLLC. Pursuant to the distribution, Mr. McNulty received 398,135 shares of common stock and Blackrobe Capital LLC received 20,101,057 shares of common stock. Mr. McNulty is the sole manager of Blackrobe Capital, LLC, but has no pecuniary interest in such shares.

Remarks:

Chief Financial Officer, Treasurer, Secretary of the Company